A Phase 1, open label trial demonstrated the safety of Fecal Microbiota Transplants in peanut allergic patients. 30% of patients increased their amount of peanut protein they consumed without reaction.
A secondary trial was completed, including an antibiotic treatment prior to the administration of FMT. In this trial, 60% patients improved their peanut protein reactivity after one FMT.
Future trials are in planning to evaluate the efficacy of prolonged administration of FMT.